ACADIA Pharmaceuticals Inc

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing medicines for neurological disorders and rare diseases. The company’s primary purpose is to address conditions with significant unmet medical needs, particularly in central nervous system indications. Acadia’s commercial portfolio includes FDA-approved therapies for Parkinson’s disease psychosis and Rett syndrome, targeting patients who often have limited treatment options. Beyond its marketed products, Acadia is actively engaged in clinical development programs in areas such as Alzheimer’s disease psychosis and Lewy body dementia psychosis, as well as additional early-stage programs in other underserved neurological conditions. Headquartered in San Diego, California, Acadia serves healthcare providers, patients, and caregivers through a combination of proprietary research, regulatory expertise, and specialized commercial capabilities. The company plays a notable role in the biopharmaceutical market segment focused on neuroscience and orphan diseases, contributing differentiated therapies to a highly specialized treatment landscape.

Sector

Healthcare

Industry

Biotechnology

CEO

Ms. Catherine E. Owen Adams

Employees

796

Headquarters

San Diego, CA, United States

Website

www.acadia.com